RSLS - ReShape Lifesciences Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.1100
-0.0175 (-13.73%)
As of 3:22PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close0.1275
Open0.1235
Bid0.0000 x 1100
Ask0.0000 x 3000
Day's Range0.1010 - 0.1275
52 Week Range0.1000 - 1,365.0000
Volume416,337
Avg. Volume100,711
Market Cap847,355
Beta (3Y Monthly)3.33
PE Ratio (TTM)N/A
EPS (TTM)-876.5070
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est32.00
Trade prices are not sourced from all markets
  • ACCESSWIRE5 days ago

    ReShape Lifesciences Announces Distribution in Australia

    SAN CLEMENTE, CA / ACCESSWIRE / April 18, 2019 / ReShape Lifesciences Inc. (RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, today announced that as of April 1, 2019, the company is selling its LAP-BAND® product in the Australian market through a relationship with Satori Healthcare. Satori Healthcare is a medical device distributor focused on the Australian bariatric market. The founder of Satori Healthcare has over 20 years of experience in the medical device industry, including 6 years of direct responsibility for LAP-BAND® while it was owned by Allergan and Apollo Endosurgery respectively.

  • ACCESSWIRE22 days ago

    ReShape Lifesciences Announces Fourth Quarter and Full Year 2018 Financial Results

    SAN CLEMENTE, CA / ACCESSWIRE / April 1, 2019 / ReShape Lifesciences Inc. (RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, today reported financial results for the three months and year ended December 31, 2018. Reported gross margins from continuing operations of 73% for the full year 2018.

  • ACCESSWIRE22 days ago

    ReShape Lifesciences, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / April 1, 2019 / ReShape Lifesciences, Inc. (OTCQB: RSLS ) will be discussing their earnings results in their 2018 Fourth Quarter Earnings to be held on April 1, 2019 at 4:30 ...

  • ACCESSWIRE22 days ago

    ReShape Lifesciences Implants First Patient in ENDURE II Trial to Support CE Marking of ReShape Vest

    SAN CLEMENTE, CA / ACCESSWIRE / April 1, 2019 / ReShape Lifesciences Inc. (RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, announced today that the company has successfully implanted its first patient in the ENDURE II trial designed to support CE Marking of the ReShape VestTM. The ReShape Vest is a minimally invasive non-anatomy changing obesity solution that restricts stomach volume without cutting, stapling, or removing the stomach. In a pilot study of 17 patients who were implanted with the ReShape Vest, early clinical results showed 85% excess weight loss at one year.

  • ACCESSWIRE25 days ago

    ReShape Lifesciences Announces $2 Million Convertible Note Financing

    SAN CLEMENTE, CA / ACCESSWIRE / March 29, 2019 / ReShape Lifesciences Inc. (RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, today announced that it has entered into a definitive agreement with certain institutional investors for a $2 million convertible note financing, which notes will be issued in a private placement. The notes will mature three months after their issuance and, if not repaid, will then initially be convertible into shares of common stock at a conversion price equal to the lesser of $0.33 and 80% of the average of the lowest two volume weighted average prices of the company's common stock during the 20 trading days prior to conversion. In connection with the financing, the company will amend the exercise price of warrants to purchase up to 8 million shares of common stock held by the investors that were issued on November 28, 2018 from $1.50 per share to $0.01 per share.

  • ACCESSWIRE28 days ago

    ReShape Lifesciences Announces Appointment of Barton P. Bandy as President and Chief Executive Officer

    SAN CLEMENTE, CA / ACCESSWIRE / March 26, 2019 / ReShape Lifesciences Inc. (RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, announced today the appointment of Barton P. Bandy as President and Chief Executive Officer effective April 1, 2019. As previously announced, Dan W. Gladney will step down as President and Chief Executive Officer on March 31, 2019 and will continue to serve as Chairman of the Board for ReShape Lifesciences.

  • ACCESSWIRElast month

    ReShape Lifesciences to Host Fourth Quarter and Full Year 2018 Conference Call on April 1, 2019

    SAN CLEMENTE, CA / ACCESSWIRE / March 19, 2019 / ReShape Lifesciences Inc. (OTCQB: RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, today announced that ...

  • ACCESSWIRE2 months ago

    ReShape Vest to be Showcased at 4th Annual Surgical Disruptive Technology Summit

    SAN CLEMENTE, CA / ACCESSWIRE / February 25, 2019 / ReShape Lifesciences Inc. (RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, announced today that the Company's ReShape VestTM will be discussed during a session at the 4th Annual Surgical Disruptive Technology Summit taking place at the JW Marriott Hotel in Houston, Texas from March 2-4, 2019. The Surgical Disruptive Technology Summit, which is hosted by the Department of Surgery at the University of Texas Health Science Center at Houston and the McGovern Medical School, is the pre-eminent educational forum for General, Bariatric, Colorectal, and Oncological Surgeons.

  • ACCESSWIRE2 months ago

    ReShape Lifesciences to Debut LAP-BAND Technology at Minimally Invasive Surgery Symposium

    SAN CLEMENTE, CA / ACCESSWIRE / February 19, 2019 / ReShape Lifesciences Inc. (OTC PINK: RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, announced today ...

  • ACCESSWIRE3 months ago

    ReShape Lifesciences Announces Chief Executive Officer Departure

    SAN CLEMENTE, CA / ACCESSWIRE / January 28, 2019 / ReShape Lifesciences Inc. (OTC Pink: RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, today announced that Dan W. Gladney has decided to step down from his role as President and Chief Executive Officer of the company effective as of March 31, 2019. The ReShape Lifesciences Board of Directors will immediately begin to search for the company's next President and Chief Executive Officer. ReShape Lifesciences™ is a medical device company focused on technologies to treat obesity and metabolic diseases.

  • ACCESSWIRE4 months ago

    Small Cap Biotech Stocks on the Rise

    HENDERSON, NV / ACCESSWIRE / December 28, 2018 / Small cap securities in the biotechnology industry are always of interest to investors because several events can help increase the stock's share price ...

  • Business Wire4 months ago

    Apollo Endosurgery, Inc. Announces the Sale of Its Surgical Product Line

    Apollo Endosurgery, Inc. (“Apollo”) (APEN), a global leader in less invasive medical devices for bariatric and gastrointestinal procedures, today announced the sale of its Surgical product line, which consists of the Lap-Band® adjustable gastric banding system and other accessories used in laparoscopic bariatric surgery, to ReShape Lifesciences Inc. (“ReShape”) (RSLS). The definitive transaction agreements were signed and closed simultaneously yesterday, December 17, 2018. This transaction will allow Apollo to focus all its efforts on growing the clinical adoption of its Endo-bariatric product offerings, which consists of its OverStitch Endoscopic Suturing Systems and the Orbera Intragastric Balloon technologies.

  • ACCESSWIRE4 months ago

    ReShape Lifesciences Acquires Lap-Band System in Exchange for ReShape Balloon

    SAN CLEMENTE, CA / ACCESSWIRE / December 18, 2018 / ReShape Lifesciences Inc. (RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, announced today that it has acquired the Lap-Band® adjustable gastric band system from Apollo Endosurgery, Inc. and that Apollo Endosurgery has acquired the ReShape Balloon™ product line from ReShape Lifesciences. ReShape Lifesciences will pay Apollo Endosurgery a total cash purchase price of $17 million, with $10.0 million dollars paid at closing and the additional $7.0 million dollars to be paid in three annual installments beginning on the first anniversary of the closing of the transaction.

  • ACCESSWIRE5 months ago

    ReShape Lifesciences Expands International Business in the Middle East

    In January 2019, Dr. Haya Ahmed Khalfan Isa Khalfan, Consultant General Surgeon at BDF Military Hospital in Bahrain will be trained at a facility in the United States on using the ReShape Balloon. Dr. Khalfan will be the first surgeon in Bahrain to be trained on the ReShape Balloon.

  • ACCESSWIRE5 months ago

    ReShape Lifesciences Announces Live Surgery Course for ReShape Vest

    SAN CLEMENTE, CA / ACCESSWIRE / December 3, 2018 / ReShape Lifesciences Inc. (RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, today announced that the Company will be holding a live-surgery surgical training for bariatric surgeons and key opinion leaders who will serve as investigators in the Company's ENDURE II trial in the European Union. The training will occur on February 4-5, 2019, in Prague, Czech Republic and is designed to provide practical experience to support initiation of the Company's ENDURE II trial in early Q1 2019. The ReShape Lifesciences ENDURE II trial is an investigative, prospective, non-randomized, multi-center study to assess the safety and effectiveness of the Reshape Vest for treatment of obese patients.

  • ACCESSWIRE5 months ago

    ReShape Lifesciences Provides Financing and Corporate Update

    As a result of the aggregate $25 million in gross proceeds raised in these recent financings and the Company's continued efforts to manage its expenses, the Company believes that it should have sufficient capital to fund its current operations into 2020. "We are really pleased with the progress we have made in getting our capital structure back to health," said Dan Gladney, Chief Executive Officer and Chairman of the Board of ReShape Lifesciences.

  • ACCESSWIRE5 months ago

    Today's Research Reports on Trending Tickers: Novelion Therapeutics and ReShape Lifesciences

    ReShape announced several encouraging developments including data regarding the treatment of type 2 diabetes mellitus but saw its shares sold off. Novelion Therapeutics Inc. shares were up 7.61% at the close yesterday with roughly 2% more seen in after-hours trading in gains. There was no significant news from the company yesterday but it was last week that the biopharmaceutical company said that General Counsel, Benjamin Harshbarger, has been appointed as interim CEO, reporting to Novelion’s Executive Chair, Mark Corrigan, M.D., effective immediately.

  • ACCESSWIRE5 months ago

    4 Healthcare Stocks Seeing New Highs On Monday

    CORAL GABLES, FL / ACCESSWIRE / November 26, 2018 / Healthcare stocks remain popular during the latest bout of selling pressure within the broader markets. The Frost & Sullivan Healthcare and Life Sciences experts are predicting big disruptions, transformationsand innovations in the coming years as the healthcare industry continues to overhaul outmoded business models. "Our interactive workshop is designed to help managers and CEOs understand key issues affecting the healthcare industry globally," noted Sandeep Sinha, Vice President & Head, Healthcare and Life Sciences, Frost & Sullivan.

  • ACCESSWIRE5 months ago

    ReShape Lifesciences Announces $10 Million Registered Direct Offering

    SAN CLEMENTE, CA / ACCESSWIRE / November 26, 2018 / ReShape Lifesciences Inc. (RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, today announced that it has entered into definitive agreements with two healthcare focused institutional investors for the purchase of 8,000,000 shares of its common stock and warrants to purchase 8,000,000 shares of its common stock, at a purchase price of $1.25 per share and associated warrants, for gross proceeds of approximately $10 million, in a registered direct offering. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. The warrants have an exercise price of $1.50 per share of common stock, will be exercisable immediately and will expire five years from the issuance date.

  • ACCESSWIRE5 months ago

    ReShape Lifesciences Presents New Data on Proprietary Technology for Type 2 Diabetes

    SAN CLEMENTE, CA / ACCESSWIRE / November 26, 2018 / ReShape Lifesciences Inc. (RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, today announced new data that was presented during a poster presentation at the recent ObesityWeek 2018 conference in Nashville, Tennessee. The poster presentation, titled "Dual Vagus Neuromodulation Improves Glycemic Control in Obese Rat and Pig Models of Type 2 Diabetes," discussed a proprietary technique developed by ReShape Lifesciences that utilizes the Company's vBlocTM technology to stimulate nerves feeding into the pancreas while simultaneously blocking nerves feeding into the liver.

  • ACCESSWIRE5 months ago

    ReShape Lifesciences Announces Third Quarter 2018 Financial Results

    SAN CLEMENTE, CA / ACCESSWIRE / November 14, 2018 / ReShape Lifesciences Inc. (NASDAQ: RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, today reported financial ...

  • ACCESSWIRE5 months ago

    4 Healthcare Stocks Investors Should Get Familiar With

    CORAL GABLES, FL / ACCESSWIRE / November 14, 2018 / The healthcare sector is the sector of the economy made up of companies that specialize in products and services related to health and medical care. As the industry continues to emerge as a leading place for investors to hedge against broader market volatility, companies like Premier Health Group, Inc. (PHGRF) (PHGI), ReShape Lifesciences Inc. (RSLS), Teladoc (TDOC), and Imprimis Pharmaceuticals, Inc. (IMMY). Premier Health Group, Inc. (PHGRF) (PHGI) is focused on developing innovative approaches that combine human skill based expertise with emerging technologies for the healthcare industry.

  • ACCESSWIRE5 months ago

    Today’s Research Reports on Stocks to Watch: ReShape Lifesciences and ABIOMED

    NEW YORK, NY / ACCESSWIRE / November 13, 2018 / It was a day of red for ReShape Lifesciences and ABIOMED on Monday. Both stocks had double digit losses despite encouraging developments reported. RDI Initiates ...

  • ACCESSWIRE5 months ago

    3 Health Care Stocks Making Moves On Monday; Premier Health Group, Inc. (OTC: PHGRF) (CSE: PHGI), Lannett Company, ReShape Lifesciences

    CORAL GABLES, FL / ACCESSWIRE / November 12, 2018 / New trends in Healthcare have helped push biotechnology stocks and healthcare stocks higher this year. Connected health is a new model for healthcare delivery, which provides healthcare services remotely. According to reports* the global connected healthcare market is expected to reach $105,337.5 Million by 2022 at a CAGR of 30.27% during the forecast period.

  • ACCESSWIRE5 months ago

    ReShape Lifesciences Completes Investigator Meeting for ReShape Vest Clinical Trial in the European Union

    SAN CLEMENTE, CA ACCESSWIRE / November 12, 2018 / ReShape Lifesciences Inc. (RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, announced today that on November 7, 2018 the company conducted an investigator meeting in conjunction with the trial in the European Union to support CE Marking of the ReShape Vest.TM The investigator meeting took place in Frankfurt, Germany and was intended to further establish relationships with the study team and to prepare investigators for the upcoming clinical trial for the ReShape Vest. Ten bariatric surgeons from The Netherlands, the Czech Republic, Germany and Belgium met with a team from ReShape Lifesciences and the group discussed the ReShape Vest technology and its proper surgical technique for use in addition to reviewing the trial protocol in anticipation of initiating study enrollment.